Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis.

J Dermatol　46,P.e339-e341　/　2019

Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse?

Clin J Gastroenterol　12,P.598-302　/　2019

Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease.

PLoS One　14,P.e0224184　/　2019

Hepatitis B virus-related hepatocellular carcinoma in young adults Efficacy of nationwide selective vaccination.

Hepatol Res　50,P.182-189　/　2019

Factors associated with longitudinal changes in serum concentrations of Mac-2 binding protein: a prospective 3-year observational study

Nutr Metab Cardiovasc Dis　29,P.1337-1344　/　2019

Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway

J Hematol Oncol.　12,P.144-144　/　2019

The reduction of miR146b-5p in monocytes and T cells could contribute to the immunopathogenesis of hepatitis C virus infection.

Sci Rep　9,P.13393　/　2019

Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium

Hepatol Int　13,P.587-598　/　2019

MEG3-derived miR-493-5p overcomes the oncogenic feature of IGF2-miR-483 loss of imprinting in hepatic cancer cells

Cell Death Dis　10,P.553　/　2019

Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan.

J Viral Hepat　26,P.1266-1275　/　2019

Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia

Exp. Ther. Med　18,P.596-604　/　2019

Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems.

Antiviral Res　169,P.104537　/　2019

Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan

Open Forum Infect Dis　6,P.ofz185　/　2019

Small Interfering RNA Screening for the Small GTPase Rab Proteins Identifies Rab5B as a Major Regulator of Hepatitis B Virus Production

J Virol　93,P.e00621　/　2019

Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma

Cancer Lett　449,P.87-98　/　2019

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis

J Hepatol　71,P.473-485　/　2019

Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection

Hepatol Commun　3,P.493-503　/　2019

Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization

Proc Natl Acad Sci U S A　116,P.8487-8492　/　2019

Clinical evaluation of a newly developed chemiluminescent enzyme immunoassay in Japan for hepatitis C virus core antigen.

Jpn J Infect Dis　72,P.285-291　/　2019

The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.

Aliment Pharmacol Ther　49,P.1230-1241　/　2019

Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. A

Ann Surg Oncol　26,P.1385-1393　/　2019

The antiviral effects of human microRNA miR-302c-3p against hepatitis B virus infection.

Aliment Pharmacol Ther　49,P.1060-1070　/　2019

CMCDG, a novel nucleoside analog with favorable safety features, exerts potent activity against wild-type and entecavir-resistant hepatitis B virus

Antimicrob Agents Chemother　63,P.e02143　/　2019

Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection

Hepatol Res　49,P.512-520　/　2019

Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma

J Gastroenterol　54,P.427-436　/　2019

Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk

Aliment Pharmacol Ther　49,P.107-115　/　2019

TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy

J Gastroenterol　54,P.339-346　/　2019

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Blood　133,P.137-146　/　2019

Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study

Hepatol Res　49,P.125-135　/　2019

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

J Gastroenterol　54,P.87-95　/　2019

Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study

J Gastroenterol Hepatol　34,P.364-369　/　2019

An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People

Hepatology　69,P.19-33　/　2019

【診断と治療のABC[142]ウイルス性肝炎】B型肝炎完全排除を目指した薬剤の開発状況

最新医学　別冊,P.150-151　/　2019

消化器内科学　Functional cureをめざすB型肝炎治療の近未来

医学のあゆみ　268,P.282-283　/　2019

【肝臓病学の未来-ウイルス性肝炎から脂肪肝と肝がんの時代へ】B型肝炎　一般診療で見落とされやすいHBV再活性化現象

内科　123,P.1111-1115　/　2019

免疫抑制療法におけるB型肝炎ウイルス再活性化の現状と方策　ステロイド単独治療中心に

日本耳鼻咽喉科学会会報　122,P.1548-1551　/　2019

検査説明Q&A　HBVマーカーを測定した際,抗原・対応する抗体が共存する症例はどのような状態なのでしょうか?

臨床検査　63,P.1176-1480　/　2019

C型肝炎ウイルス排除後の肝癌発症に関連するTLL 1遺伝子多型の同定および機能解析

Nagoya Medical Journal　56,P.145-152　/　2019

ウイルス性肝炎　今後の課題　診断から最新治療まで

東京都医学検査　47,P.117-123　/　2019

【肝炎・肝癌】ウイルス性肝炎の今後の課題

BIO Clinica　34,P.670-674　/　2019

【薬物性肝障害:新薬登場で変わる実態】特殊な病態　HBVの再活性化

消化器・肝臓内科　5,P.348-355　/　2019